Artelo Historical Financial Ratios

ARTL Stock

USD 1.06 0.01 0.95%

Artelo Biosciences is presently reporting on over 106 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.46 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Artelo Biosciences financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

About Artelo Financial Ratios Analysis

Artelo BiosciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Artelo Biosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Artelo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Artelo Biosciences history.

Artelo Biosciences Financial Ratios Chart

At this time, Artelo Biosciences' Graham Number is quite stable compared to the past year. Shareholders Equity Per Share is expected to rise to 6.82 this year, although the value of Free Cash Flow Yield is projected to rise to (1.07).

Price To Sales Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Artelo Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Artelo Biosciences sales, a figure that is much harder to manipulate than other Artelo Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most ratios from Artelo Biosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Artelo Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.At this time, Artelo Biosciences' Graham Number is quite stable compared to the past year. Shareholders Equity Per Share is expected to rise to 6.82 this year, although the value of Free Cash Flow Yield is projected to rise to (1.07).

	2019	2020	2021	2023 (projected)
Net Debt To EBITDA	0.45	0.88	0.66	0.76
Intangibles To Total Assets	0.47	0.16	0.0998	0.11

Net Debt To E B I T D A Intangibles To Total Assets

Artelo Biosciences fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Average Inventory	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets	Net Debt To E B I T D A	Current Ratio
Ptb Ratio		-0.12	0.22	0.21	0.0	-0.2	1.0	0.19	-0.3	0.23	-0.08	-0.15	-0.25	0.28	0.2	-0.25	0.39	-0.29	-0.24	-0.43	0.69	-0.24	0.22	0.11	0.41	0.24
Book Value Per Share	-0.12		-0.59	-0.62	-0.1	0.63	-0.12	-0.77	-0.21	-0.37	-0.01	0.97	0.45	-0.48	-0.59	0.46	0.75	-0.23	0.46	0.46	0.31	0.46	-0.33	0.05	0.14	-0.04
Free Cash Flow Yield	0.22	-0.59		0.46	-0.12	-0.92	0.22	0.46	0.12	0.37	-0.48	-0.55	-0.67	0.89	0.93	-0.67	-0.08	0.12	-0.67	-0.69	-0.29	-0.67	0.95	0.42	0.24	-0.24
Operating Cash Flow Per Share	0.21	-0.62	0.46		0.16	-0.35	0.21	0.97	-0.53	0.95	0.11	-0.67	-0.5	0.56	0.31	-0.5	-0.38	-0.51	-0.49	-0.51	0.19	-0.49	0.3	-0.34	0.27	0.47
Average Payables	0.0	-0.1	-0.12	0.16		-0.06	0.0	0.13	0.01	0.15	0.86	-0.06	0.0	-0.1	-0.07	0.0	-0.26	0.01	0.0	0.0	0.06	0.0	-0.16	-0.26	0.11	0.07
Capex To Depreciation	-0.2	0.63	-0.92	-0.35	-0.06		-0.2	-0.37	-0.26	-0.24	0.35	0.58	0.66	-0.87	-0.99	0.66	0.12	-0.26	0.66	0.69	0.38	0.66	-0.86	-0.54	-0.18	0.41
Pb Ratio	1.0	-0.12	0.22	0.21	0.0	-0.2		0.19	-0.3	0.23	-0.08	-0.15	-0.25	0.28	0.2	-0.25	0.39	-0.29	-0.24	-0.43	0.69	-0.24	0.22	0.11	0.41	0.24
Free Cash Flow Per Share	0.19	-0.77	0.46	0.97	0.13	-0.37	0.19		-0.41	0.86	0.12	-0.81	-0.45	0.52	0.33	-0.46	-0.54	-0.39	-0.45	-0.47	0.11	-0.45	0.24	-0.31	0.19	0.46
Roic	-0.3	-0.21	0.12	-0.53	0.01	-0.26	-0.3	-0.41		-0.72	-0.1	-0.04	0.14	-0.21	0.25	0.14	-0.33	1.0	0.14	0.18	-0.63	0.14	0.08	0.13	-0.42	-0.48
Net Income Per Share	0.23	-0.37	0.37	0.95	0.15	-0.24	0.23	0.86	-0.72		0.09	-0.45	-0.48	0.56	0.21	-0.49	-0.13	-0.71	-0.48	-0.5	0.31	-0.48	0.28	-0.29	0.36	0.46
Average Inventory	-0.08	-0.01	-0.48	0.11	0.86	0.35	-0.08	0.12	-0.1	0.09		0.0	0.27	-0.44	-0.47	0.27	-0.35	-0.1	0.27	0.28	0.2	0.27	-0.56	-0.51	-0.03	0.32
Cash Per Share	-0.15	0.97	-0.55	-0.67	-0.06	0.58	-0.15	-0.81	-0.04	-0.45	0.0		0.5	-0.51	-0.54	0.5	0.71	-0.06	0.5	0.51	0.25	0.5	-0.29	-0.01	0.15	-0.04
Pocfratio	-0.25	0.45	-0.67	-0.5	0.0	0.66	-0.25	-0.45	0.14	-0.48	0.27	0.5		-0.75	-0.66	1.0	0.1	0.14	1.0	0.98	0.31	1.0	-0.65	-0.37	0.03	0.37
Interest Coverage	0.28	-0.48	0.89	0.56	-0.1	-0.87	0.28	0.52	-0.21	0.56	-0.44	-0.51	-0.75		0.89	-0.75	0.08	-0.21	-0.75	-0.78	-0.15	-0.75	0.87	0.53	0.35	-0.24
Capex To Operating Cash Flow	0.2	-0.59	0.93	0.31	-0.07	-0.99	0.2	0.33	0.25	0.21	-0.47	-0.54	-0.66	0.89		-0.66	-0.07	0.26	-0.66	-0.69	-0.39	-0.66	0.89	0.58	0.18	-0.43
Pfcf Ratio	-0.25	0.46	-0.67	-0.5	0.0	0.66	-0.25	-0.46	0.14	-0.49	0.27	0.5	1.0	-0.75	-0.66		0.1	0.14	1.0	0.98	0.31	1.0	-0.65	-0.37	0.03	0.37
Income Quality	0.39	0.75	-0.08	-0.38	-0.26	0.12	0.39	-0.54	-0.33	-0.13	-0.35	0.71	0.1	0.08	-0.07	0.1		-0.35	0.1	0.01	0.48	0.1	0.19	0.4	0.43	-0.11
Roe	-0.29	-0.23	0.12	-0.51	0.01	-0.26	-0.29	-0.39	1.0	-0.71	-0.1	-0.06	0.14	-0.21	0.26	0.14	-0.35		0.14	0.18	-0.63	0.14	0.08	0.12	-0.42	-0.47
Ev To Operating Cash Flow	-0.24	0.46	-0.67	-0.49	0.0	0.66	-0.24	-0.45	0.14	-0.48	0.27	0.5	1.0	-0.75	-0.66	1.0	0.1	0.14		0.98	0.32	1.0	-0.65	-0.37	0.04	0.38
Pe Ratio	-0.43	0.46	-0.69	-0.51	0.0	0.69	-0.43	-0.47	0.18	-0.5	0.28	0.51	0.98	-0.78	-0.69	0.98	0.01	0.18	0.98		0.16	0.98	-0.68	-0.38	-0.05	0.32
Return On Tangible Assets	0.69	0.31	-0.29	0.19	0.06	0.38	0.69	0.11	-0.63	0.31	0.2	0.25	0.31	-0.15	-0.39	0.31	0.48	-0.63	0.32	0.16		0.32	-0.26	-0.32	0.6	0.72
Ev To Free Cash Flow	-0.24	0.46	-0.67	-0.49	0.0	0.66	-0.24	-0.45	0.14	-0.48	0.27	0.5	1.0	-0.75	-0.66	1.0	0.1	0.14	1.0	0.98	0.32		-0.65	-0.37	0.04	0.38
Earnings Yield	0.22	-0.33	0.95	0.3	-0.16	-0.86	0.22	0.24	0.08	0.28	-0.56	-0.29	-0.65	0.87	0.89	-0.65	0.19	0.08	-0.65	-0.68	-0.26	-0.65		0.55	0.28	-0.36
Intangibles To Total Assets	0.11	0.05	0.42	-0.34	-0.26	-0.54	0.11	-0.31	0.13	-0.29	-0.51	-0.01	-0.37	0.53	0.58	-0.37	0.4	0.12	-0.37	-0.38	-0.32	-0.37	0.55		0.04	-0.72
Net Debt To E B I T D A	0.41	0.14	0.24	0.27	0.11	-0.18	0.41	0.19	-0.42	0.36	-0.03	0.15	0.03	0.35	0.18	0.03	0.43	-0.42	0.04	-0.05	0.6	0.04	0.28	0.04		0.53
Current Ratio	0.24	-0.04	-0.24	0.47	0.07	0.41	0.24	0.46	-0.48	0.46	0.32	-0.04	0.37	-0.24	-0.43	0.37	-0.11	-0.47	0.38	0.32	0.72	0.38	-0.36	-0.72	0.53

Click cells to compare fundamentals

Artelo Biosciences Account Relationship Matchups

Artelo Biosciences fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	0.77	0.92	1.41	0.42	0.49	0.46
Book Value Per Share	37.93	15.69	9.67	6.85	6.17	6.82
Free Cash Flow Yield	(1.02)	(1.22)	(0.36)	(0.98)	(1.13)	(1.07)
Operating Cash Flow Per Share	(19.39)	(17.6)	(4.93)	(2.83)	(3.25)	(3.41)
Pb Ratio	0.77	0.92	1.41	0.42	0.49	0.46
Free Cash Flow Per Share	(29.82)	(17.6)	(4.93)	(2.83)	(3.25)	(3.41)
Roic	(0.0348)	(1.19)	(0.61)	(0.52)	(0.6)	(0.57)
Net Income Per Share	(15.08)	(18.85)	(5.97)	(3.49)	(4.01)	(4.21)
Cash Per Share	30.72	8.67	8.08	6.19	5.57	5.92
Pocfratio	(1.51)	(0.82)	(2.77)	(1.02)	(0.92)	(0.97)
Pfcf Ratio	(0.98)	(0.82)	(2.77)	(1.02)	(0.92)	(0.97)
Income Quality	1.29	0.93	0.83	0.79	0.71	0.7
Roe	(0.4)	(1.2)	(0.62)	(0.51)	(0.59)	(0.56)
Ev To Operating Cash Flow	0.0759	(0.33)	(1.71)	(0.17)	(0.15)	(0.16)
Pe Ratio	(1.94)	(0.76)	(2.29)	(0.83)	(0.75)	(0.78)
Return On Tangible Assets	(0.49)	(1.99)	(0.7)	(0.54)	(0.48)	(0.51)
Ev To Free Cash Flow	0.0494	(0.33)	(1.71)	(0.17)	(0.15)	(0.16)
Earnings Yield	(0.52)	(1.31)	(0.44)	(1.21)	(1.39)	(1.32)
Net Debt To E B I T D A	0.14	1.05	0.45	0.88	0.66	0.76
Current Ratio	4.35	4.65	19.61	18.36	16.52	17.35
Tangible Book Value Per Share	23.76	7.43	8.03	6.13	5.52	4.62
Graham Number	113.45	81.56	36.06	23.18	20.87	28.01
Shareholders Equity Per Share	37.93	15.69	9.67	6.85	6.17	6.82
Graham Net Net	23.64	6.64	7.61	5.83	5.25	4.42
Enterprise Value Over E B I T D A	(2.36)	0.0503	(0.3)	(1.41)	(0.13)	(0.12)
Price Earnings Ratio	(1.94)	(0.76)	(2.29)	(0.83)	(0.75)	(0.78)
Price Book Value Ratio	0.77	0.92	1.41	0.42	0.49	0.46
Price Earnings To Growth Ratio	0.0426	(0.0299)	0.0335	0.02	0.0229	0.0218
Price To Operating Cash Flows Ratio	(1.51)	(0.82)	(2.77)	(1.02)	(0.92)	(0.97)
Price To Free Cash Flows Ratio	(0.98)	(0.82)	(2.77)	(1.02)	(0.92)	(0.97)
Effective Tax Rate	0.94	0.013	5.38E-4	0.0207	0.0238	0.0226
Return On Capital Employed	17.36	(0.59)	(1.21)	(0.61)	(0.53)	(0.58)
Quick Ratio	4.36	4.65	19.61	18.36	16.52	17.35
Cash Ratio	4.33	4.27	12.6	6.9	7.94	8.0
Price To Book Ratio	0.77	0.92	1.41	0.42	0.49	0.46
Price Cash Flow Ratio	(1.51)	(0.82)	(2.77)	(1.02)	(0.92)	(0.97)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:

How To Invest In Artelo

Details

Is Artelo Stock a good investment?

Details

What is Artelo Biosciences' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.87)

Return On Assets

(0.54)

Return On Equity

(0.89)

The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Artelo Historical Financial Ratios

About Artelo Financial Ratios Analysis

Artelo Biosciences Financial Ratios Chart

Price To Sales Ratio

Artelo Biosciences fundamentals Correlations

Artelo Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Artelo Biosciences fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Roe	+ 1.0	Roic
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Free Cash Flow	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pfcf Ratio

Capex To Operating Cash Flow	- 0.99	Capex To Depreciation
Capex To Depreciation	- 0.92	Free Cash Flow Yield
Interest Coverage	- 0.87	Capex To Depreciation
Earnings Yield	- 0.86	Capex To Depreciation
Cash Per Share	- 0.81	Free Cash Flow Per Share
Pe Ratio	- 0.78	Interest Coverage